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Summary
 
The barrier function of mitochondrial membranes is perturbed early during the apoptotic pro-
cess. Here we show that the mitochondria contain a caspase-like enzymatic activity cleaving
the caspase substrate Z-VAD.afc, in addition to three biological activities previously suggested
to participate in the apoptotic process: (a) cytochrome 
 
c
 
; (b) an apoptosis-inducing factor (AIF)
which causes isolated nuclei to undergo apoptosis in vitro; and (c) a DNAse activity. All of
these factors, which are biochemically distinct, are released upon opening of the permeability
transition (PT) pore in a coordinate, Bcl-2–inhibitable fashion. Caspase inhibitors fully neutral-
ize the Z-VAD.afc–cleaving activity, have a limited effect on the AIF activity, and have no ef-
fect at all on the DNase activities. Purification of proteins reacting with the biotinylated caspase
substrate Z-VAD, immunodetection, and immunodepletion experiments reveal the presence
of procaspase-2 and -9 in mitochondria. Upon induction of PT pore opening, these pro-
caspases are released from purified mitochondria and become activated. Similarly, upon induc-
tion of apoptosis, both procaspases redistribute from the mitochondrion to the cytosol and are
processed to generate enzymatically active caspases. This redistribution is inhibited by Bcl-2.
Recombinant caspase-2 and -9 suffice to provoke full-blown apoptosis upon microinjection
into cells. Altogether, these data suggest that caspase-2 and -9 zymogens are essentially localized
in mitochondria and that the disruption of the outer mitochondrial membrane occurring early
during apoptosis may be critical for their subcellular redistribution and activation.
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T
 
he process of apoptosis can be subdivided into three
functionally distinct phases: (a) the initiation phase,
during which a number of “private” signal transduction or
damage pathways are activated in a stimulus-dependent
fashion; (b) the common effector/decision phase, during
which the cell “decides” to die; and (c) the degradation
phase, beyond regulation, during which the cells acquire
the morphological and biochemical hallmarks of apoptosis
(1–3). Much of the data obtained by us (4–10) and our col-
leagues (11–17) are compatible with the notion that the
disruption of mitochondrial membrane barrier function
constitutes the decisive event of apoptosis (see also refer-
ences cited in 18–20). This suggests a scenario in which the
initiation phase is mainly premitochondrial, the effector/
decision phase is essentially mitochondrial, and the degra-
dation phase is postmitochondrial.
A wealth of data suggests that the mitochondrion can
function as an integrator of very different proapoptotic
stimuli. Thus, unfavorable metabolic conditions facilitate
opening of the mitochondrial permeability transition (PT)
 
1
 
pore: reactive oxygen species, depletion of glutathione, de-
 
1
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pletion of NAD(P)H
 
2
 
, depletion of ADP/ATP, or supra-
physiological levels of cytosolic Ca
 
2
 
1
 
. Opening of the PT
pore then causes a dissipation of the inner mitochondrial
transmembrane potential (
 
DC
 
m), an increase in the matrix
volume, and the mechanical disruption of the outer mito-
chondrial membrane (18–23). These mitochondrial changes
also occur during apoptosis in an order that may depend on
the cell type and on the death trigger (4–17). Multiple
proapoptotic molecules have been shown to permeabilize
the inner and/or outer membrane of purified mitochondria
in vitro. This applies to apical caspases (10, 24), ceramide-
induced cytosolic factors (24), amphipathic peptides (e.g.,
mastoparan, reaper, 
 
b
 
-amyloid [25–27]), and proapoptotic
members of the Bcl-2 family (Bax, Bak, BH3 peptides [28–
31]). In contrast, Bcl-2 and Bcl-X
 
L
 
 stabilize the mito-
chondrial membrane barrier function (5–8, 10–17). One
prominent target of several of these agents is the PT pore
complex (PTPC), a multiprotein structure formed in the
contact site between the inner and outer mitochondrial
membranes. The purified PTPC permeabilizes membranes
in response to Ca
 
2
 
1
 
, oxidative stress, thiol cross-linking, and
caspases (10). Recombinant Bcl-2 or Bcl-X
 
L
 
 has a direct
inhibitory effect on PTPC (10). Thus, the mitochondrial
PT pore (and perhaps additional mitochondrial structures)
can integrate distinct apoptosis-inducing and apoptosis-
inhibitory pathways.
Although there is no doubt that mitochondrial mem-
brane function is perturbed during cell death, the mecha-
nisms linking these perturbations to apoptosis are not
completely elucidated. Cytochrome 
 
c
 
, which is normally
sequestered in the mitochondrial intermembrane space, has
been shown to be released through the mitochondrial
outer membrane early during apoptosis (13) and to interact
with Apaf-1 and dATP (or ATP), as well as procaspase-9 in
a reaction that culminates in the proteolytic activation of
the caspase-9 zymogen (32, 33). Caspase-9 then can pro-
cess and activate procaspase-3 (32), and caspase-3 can acti-
vate DNA fragmentation factor (DFF)/caspase-activated
DNAse (CAD), a DNAse which would be responsible for
DNA fragmentation (34, 35). In some experimental sys-
tems, cytochrome 
 
c 
 
(14 kD) appears to be the sole stable
rate-limiting protein necessary for the activation of this or
similar cascades leading to caspase-3 activation and DNA
fragmentation in vitro (13, 15). However, at least one labile
factor, apoptosis-inducing factor (AIF; 
 
z
 
50 kD), has been
purified from the mitochondrial intermembrane space and
has been defined by its capacity to induce nuclear apoptosis
in cell-free systems in which no other mitochondrial or cy-
tosolic proteins are present (7, 8, 24). Moreover, it must be
stressed that changes in mitochondrial membrane perme-
ability are lethal for the cell, even in conditions in which
caspases are inhibited. In such conditions, PT pore opening
causes a nonapoptotic pattern of cytolysis (9, 36), shedding
doubts on the role of caspases as principal “executioners” of
the death process (37, 38). Undoubtedly, however, caspases
are important for the acquisition of apoptotic morphology
(9, 36–39).
Stimulated by these premises, we decided to characterize
 
the mitochondrial factors released after opening of the PT
pore. Here, we show that at least four potentially apopto-
genic proteins are released from mitochondria after open-
ing of the PT pore in a Bcl-2–regulated fashion. In addi-
tion to cytochrome 
 
c
 
 and AIF, mitochondrial supernatants
contain a DNAse activity and protease cleaving the caspase
substrate Z-VAD.afc. These proteins are different from
each other, based on their chromatographic separation and
on their response to inhibitors. Most of the Z-VAD.afc–
cleaving activity is due to the presence of caspase-2 and -9,
which are present in mitochondria of different organs and
which redistribute to the cytosol during apoptosis induc-
tion. These findings suggest the existence of several inde-
pendent pathways linking opening of the PT pore to the
commencement of apoptotic degradation.
 
Materials and Methods
 
Animals and Cell Lines.
 
Female Balb/c mice (4–12 wk old)
were killed by cervical dislocation, and organs were removed im-
mediately and placed into ice-cold homogenization buffer (300
mM saccharose, 5 mM 
 
N
 
-tris[hydroxymethyl]methyl-2-amino-
ethanesulfonic acid (TES), 200 
 
m
 
M EGTA, pH 7.2), followed by
purification of mitochondria according to standard protocols (8).
2B4.11 T cell hybridoma cell lines stably transfected with an
SFFV.neo vector containing the human bcl-2 gene or the neo-
mycin (Neo) resistance gene only were provided by Jonathan
Ashwell (National Institutes of Health, Bethesda, MD [40]).
These cell lines, as well as human fibroblast–like HeLa cells,
were cultured in RPMI 1640 medium supplemented with
 
l
 
-glutamine, antibiotics, and 10% decomplemented FCS. Cell
death was induced by addition of 1 
 
m
 
M staurosporine or 1 
 
m
 
M
dexamethasone (DEX; Sigma Chemical Co.). Rat-1 cells were a
gift from David Andrews (McMaster University, Hamilton, On-
tario, Canada [41]) and were cultured in supplemented MEM.
 
Induction of PT.
 
Mitochondria were resuspended in CFS buf-
fer (220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM
KH
 
2
 
PO
 
4
 
, 0.5 mM EGTA, 2 mM MgCl
 
2
 
, 5 mM pyruvate, 0.1
mM PMSF, 1 
 
m
 
g/ml leupeptin, 1 
 
m
 
g/ml pepstatin A, 50 
 
m
 
g/ml
antipain, 10 
 
m
 
g/ml chymopapain, 1 mM dithiothreitol, 10 mM
Hepes-NaOH, pH 7.4) and incubated in the presence or absence
of atractyloside (Atr, 5 mM; 30 min, room temperature [RT]),
followed by centrifugation (7,000 
 
g
 
, 10 min, 4
 
8
 
C), recovery of
the supernatant, and ultracentrifugation (1.5 
 
3 
 
10
 
5
 
 
 
g
 
, 1 h, 4
 
8
 
C).
This supernatant was then subjected to functional or biochemical
analysis. In several experiments, the opening of the PT pore was
prevented by preincubation (15 min) of mitochondria with cy-
closporin A (CsA, 1 
 
m
 
M; Novartis) or bongkrekic acid (BA; pro-
vided by Dr. J.A. Duine, Delft University, Delft, The Nether-
lands). For purification of intermembrane proteins, mitochondria
were subjected to hypotonic shock (50 mM Hepes-KOH, pH
6.75), followed by the same steps of centrifugation described
above. This protocol only disrupts the outer mitochondrial mem-
brane, as confirmed by electron microscopic analysis.
 
Immunodepletion and Immunoblots.
 
A mouse anti-cytochrome
 
c 
 
mAb (6H2.B4; PharMingen [13]), an isotype-matched anti–IL-2
antibody (PharMingen), a polyclonal goat antiserum specific for
caspase-2 (N19 [Santa Cruz Biotechnology], directed against
amino acids 3–21 of NH
 
2
 
 terminus), or a rabbit antibody directed
against caspase-9 (Hazelton Research Products, Inc.; generated
against the large subunit) was immobilized on protein A and pro- 
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tein G agarose beads (Santa Cruz Biotechnology; 100–200 
 
m
 
g of
antibody per ml beads, 3 h at RT, three washes in Hepes-KOH,
pH 6.75). 100 
 
m
 
l of packed beads was incubated with the super-
natant of Atr-treated mitochondria (0.5 
 
m
 
g/ml protein) in a 1 ml
vol for 5–18 h at 4
 
8
 
C, followed by removal of beads (2,000 
 
g
 
, 10
min at 4
 
8
 
C) and testing of the supernatant. Immunoblots were
performed on SDS-PAGE–migrated (12–15%, reducing condi-
tions) proteins using these antibodies, as well as an anti-cyto-
chrome 
 
c 
 
antibody (7H8.2C12; PharMingen). In those experi-
ments in which proteins were biotinylated (see below), the
presence of biotin was revealed using a neutralin-avidin–horse-
radish peroxidase conjugate (Southern Biotechnology Associates).
 
Quantitation of AIF Activity, Z-VAD.afc Cleavage, and DNAse
Assay.
 
AIF was quantified by virtue of its capacity to induce
DNA fragmentation in purified nuclei, as described (8, 24). In
brief, purified HeLa cell nuclei were incubated in CFS buffer
containing variable amounts of mitochondrial proteins, which
were preincubated (15 min, 37
 
8
 
C) with different inhibitors:
 
N
 
-phenylmaleimide, chloromercuryphenylsulfonic acid, iodoac-
etamide, aurinetricarboxylic acid (ATA), ZnCl
 
2
 
, EGTA (Sigma
Chemical Co.), or modified peptides containing NH
 
2
 
-terminal
 
N
 
-benzyloxycarbonyl (Z) and COOH-terminal fluoromethylke-
tone (fmk) groups (Z-VAD.fmk, Z-YVAD.fmk, Z-DEVD.fmk
[Enzyme Systems]). After 90 min of incubation at 37
 
8
 
C, cells
were stained with propidium iodine (10 
 
m
 
g/ml, 5 min), and the
nuclei were analyzed in a cytofluorimeter to determine the fre-
quency of hypoploid nuclei (8, 24). Alternatively, mitochondrial
proteins were examined for the cleavage of synthetic peptide sub-
strates containing COOH-terminal 7-amino-4-trifluoromethyl
coumarin (afc). In brief, Z-VAD.afc (100 
 
m
 
M in CFS buffer) was
incubated (30 min, 37
 
8
 
C) with the indicated dose of mitochon-
drial intermembrane proteins, followed by fluorometric analysis
(excitation: 400 nm; emission: 505 nm) using a fluorescence
spectrometer (model F4500; Hitachi). Endonuclease activity was
determined on supercoiled pUC DNA (500 ng in CFS buffer; 90
min, 37
 
8
 
C), followed by ethidium bromide agarose gel (1%) elec-
trophoresis, as described (7).
 
Submitochondrial Fractionation, and Immunoelectron Microscopy.
 
Submitochondrial fractions (matrix, inner membrane, intermem-
brane space, outer membrane) were obtained following standard
methods (42). The identity of each submitochondrial fraction was
checked by the determination of suitable marker enzymes, as de-
scribed (8). Thus, the intermembrane fraction was found to be
only poorly contaminated with matrix proteins (5% of malate de-
hydrogenase activity per milligram of protein compared with the
matrix), inner membrane proteins (0.3% of succinate dehydroge-
nase activity compared with purified inner membrane proteins),
and outer membrane proteins (0.4% of monoamine oxidase ac-
tivity compared with purified outer membrane proteins). Immu-
noelectron microscopy was performed using the rabbit anti–
caspase-9 antibody and an Immunogold (5 nm) anti–rabbit Ig
conjugate (Amersham Pharmacia Biotech). Control staining per-
formed with preimmune rabbit antisera revealed low background
levels (
 
,
 
0.1 gold particles/mitochondrion).
 
Purification of Biological Activities Contained in the Mitochondrial
Intermembrane Space.
 
All purification steps were carried out using
a SMART
 
®
 
 system (Amersham Pharmacia Biotech) kept at 4
 
8
 
C.
Mitochondrial intermembrane proteins in 50 mM Hepes-KOH
(pH 6.75) were injected (40 
 
m
 
g proteins/100 
 
m
 
l per injection) into
a MiniS column (PC 3.2./3) preequilibrated with 50 mM Hepes-
KOH (pH 6.75) and eluted (400 
 
m
 
l/min) with 50 mM Hepes-
KOH containing variable amounts of NaCl. AIF-containing ma-
terial, which is retained in this column and eluted with 25 mM
 
NaCl at 2.5 min, was precipitated with acetone (90%, 
 
2
 
20
 
8
 
C,
overnight; 8,700 
 
g
 
, 20 min, 4
 
8
 
C), washed with 70% acetone,
dried in nitrogen, and resuspended in CFS buffer (for quantifica-
tion in the cell-free system) or 50 mM K
 
2
 
HPO
 
4
 
/KH
 
2
 
PO
 
4
 
 buffer
(pH 7.0) containing 2 M (NH
 
4
 
)2SO
 
4
 
 (for further purification).
The flow-through of the MiniS column was loaded onto a FAST
desalting column (PC 3.2/10), recovered in 2 ml 50 mM Tris-
HCl (pH 8.5), applied to a MiniQ column (PC 3.2./3), eluted on
a linear gradient (0–1 M NaCl in 15 min; 400 
 
m
 
l/min), and sub-
jected to biological and enzymatic tests. The eluate obtained at
280 mM NaCl, which contains maximum Z-VAD.afc–cleaving
activity, was incubated with biotinylated VAD.fmk (20 
 
m
 
M, 30
min, 37
 
8
 
C; Enzyme Systems), and biotinylated proteins were re-
tained on an ImmunoPure
 
®
 
 monomeric avidin column (Pierce
Chemical Co.) and eluted with excess biotin following the man-
ufacturer’s protocol.
 
Microinjection of Cells.
 
Microinjection was performed using an
Axiovert 100 inverted microscope (Carl Zeiss, Inc.) fitted with an
Eppendorf pressure injector (model 5246) and micromanipulator
(model AIS 45744; Carl Zeiss, Inc.). Microinjection needles
(
 
z
 
0.1-
 
m
 
m inner diameter) were made from glass capillaries using
a horizontal electrode puller (Fleming Brown micropipet puller,
model P-87; Sutter Instruments). Rat-1 cells were plated on glass
coverslips (Erie Scientific) 
 
.
 
12 h before injection. To identify
injected cells, the injectate contained 0.25% (wt/vol) solution of
FITC-conjugated dextran (Molecular Probes) in PBS buffer (pH
7.2). Dye alone or dye plus recombinant caspase (produced as ac-
tive enzymes [43, 44]) were injected into the cytoplasm (pressure
150 hPa; 0.2 s) of cells cultured in complete culture medium
(RPMI 1640 plus 5% FCS), optionally supplemented with 100
 
m
 
M Z-VAD.fmk. For control purposes, cells were cultured with
etoposide (1 
 
m
 
g/ml, 6 h). 90 min after microinjection, cells were
stained with 1 
 
m
 
M Hoechst 33342 dye or with biotinylated An-
nexin V (Boehringer Mannheim) (revealed with a streptavidin-
PE conjugate from Sigma Chemical Co.). Injected, viable cells
(FITC
 
1
 
 cells; green fluorescence), usually 100–200 per experi-
ment, were identified by fluorescence microscopy. After visual
identification of microinjected cells, only the blue or the red flu-
orescence was recorded using Ektapress pj400 films (Eastman
Kodak Co.).
 
Immunofluorescence Analysis.
 
Cells were fixed with 4% para-
formaldehyde, 0.19% picric acid in PBS (pH 7.4) for 1 h at RT.
Fixed cells were permeabilized with 0.1% SDS in PBS at RT for
5 min, blocked with 2% FCS, and stained with an mAb specific
for native cytochrome 
 
c 
 
(6H2.B4; PharMingen), polyclonal anti-
sera against caspase-2 or -9, and were revealed by appropriate
FITC-labeled secondary antibodies.
 
Results
 
Three Potentially Apoptogenic, Cytochrome c–independent Bi-
ological Activities Are Released from Mitochondria in a Coordi-
nate, Bcl-2–regulated Fashion.
 
Addition of Atr, a ligand of
the adenine nucleotide translocator, causes isolated liver
mitochondria to open the PT pore and physically disrupts
the outer but not the inner mitochondrial membrane (6,
23). The supernatant of Atr-treated mitochondria thus
contains water-soluble intermembrane proteins, including
cytochrome 
 
c 
 
(23, 45; Fig. 1, D and H). In addition, it con-
tains three different biological activities potentially relevant
for the apoptotic degradation phase: (a) an AIF activity 
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which causes isolated nuclei to undergo chromatin con-
densation and DNA loss (8, 24); (b) an activity which
cleaves several caspase substrates, the optimal substrate
being Z-VAD.afc (Z-VAD.afc 
 
$ 
 
Z-DEVD.afc 
 
$
 
Z-YVAD.afc 
 
. 
 
Z-VDVAD.afc 
 
.. 
 
Z-VEID.afc) (Fig. 1
B); and (c) a DNAse capable of digesting purified plasmid
DNA (Fig. 1 C). Of note, it appears that the as yet unchar-
acterized mitochondrial DNAse capable of digesting puri-
fied DNA differs from previously described mitochondrial
DNAse, such as endonuclease G, which acts in a sequence-
specific fashion (46). None of these biological activities is
affected by immunodepletion of cytochrome 
 
c (Fig. 1,
A–D).  These data indicate that the presence of cytochrome c is
not rate-limiting for the activation of these molecules. Cy-
tochrome c and the three biological activities (AIF, Z-VA-
Dase, and DNAse) are released by Atr (Fig. 1, E–H) as well
as by other PT pore opening agents such as Ca21 or the re-
active oxygen species donor tert-butylhydroperoxide (not
shown). Cytochrome c, AIF, Z-VADase, and DNAse have
been detected in the supernatant of Atr-treated mitochon-
dria from different sources, including liver (Fig. 1, A–K), T
cells (Fig. 1, E–H), heart, kidney, and brain (not shown).
When the effect of Atr on the PT pore is blocked by BA or
CsA, no such release occurs (Fig. 1, E–H). Similarly, trans-
fection-enforced overexpression of Bcl-2 can prevent the
release of all three biological activities (Fig. 1, E–H). Thus,
the release of these factors occurs in a coordinate, Bcl-2–
regulated fashion.
Chromatographic Separation of a Caspase-like Activity, a
DNAse, and AIF. The supernatant of Atr-treated mito-
chondria was diluted in 50 mM Hepes-KOH at pH 6.75
and applied to a cation exchange (MiniS) column (Fig. 2).
In these conditions, part of the AIF activity is retained in
the column and can be eluted with 25 mM NaCl (Fig. 3, A
and B). This latter preparation can be subjected to differen-
tial acetone precipitation, applied to a phenyl superose col-
Figure 1. Three biological ac-
tivities not requiring cytochrome
c are coordinately released into
the supernatant of mitochon-
dria. (A) AIF activity not requir-
ing cytochrome c. Supernatants
of Atr-treated liver mitochondria
were immunodepleted of cyto-
chrome c or sham-immunode-
pleted using an anti–IL-2 anti-
body and tested for their capacity
to induce hypoploidy in isolated
HeLa nuclei in a cell-free system
of apoptosis. (B) A Z-VAD.afc–
cleaving activity not relying on
the presence of cytochrome c.
The same supernatants as in A
were incubated with the fluoro-
genic caspase substrate Z-VAD.
afc, and afc-dependent fluores-
cence was measured. (C) A
DNAse activity not requiring
cytochrome c. The mitochon-
drial supernatant (60 mg/ml) was
incubated with purified super-
coiled plasmid DNA (pUC), fol-
lowed by horizontal agarose gel
electrophoresis and detection of
DNA with ethidium bromide.
(D) Control of cytochrome c de-
pletion by immunoblot. Super-
natants of control mitochondria
(Co.) or Atr-treated mitochon-
dria (lanes 1–6) were left un-
treated (lane 1) or subjected to
immunodepletion with antibod-
ies specific for IL-2 (lane 2) or
cytochrome c (lane 3). In addi-
tion, the immunocomplexes im-
mobilized by beads were ana-
lyzed for the presence of
cytochrome  c (lane 4, anti–IL-2;
lane 5, anti-cytochrome c; lane 6, no antibody). (E–H) Mitochondria purified from liver or T cell hybridoma cells expressing Bcl-2 or a Neo control vec-
tor were treated with the indicated combination of Atr, BA, and/or CsA and tested for AIF activity (E), Z-VAD.afc–cleaving activity (F), DNAse activity
(G), or cytochrome c (H). (I–K) Inhibitory effect of Z-VAD.fmk. The supernatant of Atr-treated hepatocyte mitochondria was treated with Z-VAD.fmk
(50 mM, 15 min) and tested for AIF activity (I) and for Z-VAD.afc–cleaving activity at two different protein concentrations (J) and for DNAse activity
(K) at 40 mg protein/ml. In addition, the effect of ATA (5 mM) on the DNAse activity was assessed (K).385 Susin et al.
umn, and eluted as z50-kD AIF activity by reducing the
salt concentration on a linear gradient, at a concentration of
400 to 200 mM (NH4)2SO4 (8; Fig. 2). Cytochrome c, the
Z-VADase, and the DNAse were found in the flow-
through of the MiniS column in the same conditions in
which part of the AIF activity was retained (Fig. 3, C and
D). The flow-through containing these activities can be
applied to a cation exchange (MiniQ) column (Fig. 2, and
Fig. 4 A), yielding a complete separation of residual AIF ac-
tivity (Fig. 4 B), cytochrome c (not shown), the Z-VADase
(Fig. 4 C), and the DNAse (Fig. 4 D), which elute at differ-
ent levels of ionic strength (70, 200, 280, and 540 mM
NaCl, respectively). These data indicate the presence of
three biochemically distinct activities in the mitochondrial
supernatant. Again, these activities are separate from cyto-
chrome c.
Distinct Inhibitory Profiles of Caspase-like Activity, DNAse,
and AIF. The notion that the three biological activities
detected in the mitochondrial intermembrane space are dis-
tinct is confirmed by their disparate inhibitory profiles (Fig.
1, I–K, and Fig. 4, E–G). AIF is not inhibited by EGTA or
by Zn21. In contrast, EGTA or Zn21 inhibit the DNAse
(Fig. 4, E and G). Neither AIF nor DNAse are inhibited by
ATA (Fig. 1 K), indicating that they are distinct from DFF/
CAD, which is inhibited by ATA (35, 47). Different
caspase inhibitors (Z-VAD.fmk, Z-YVAD.fmk, and
Z-DEVD.fmk, ID50 , 10 mM) and thiol-reactive agents
(iodoacetamide, ID50 z 250 mM), as well as Zn21 (ID50 z 10
mM) (which inhibits caspases [48]), can completely inhibit
the Z-VADase activity (Fig. 1 J, and Fig. 4 F). These agents
also tend to reduce the AIF activity, though with a higher
ID50, when added to the mitochondrial supernatant after
induction of PT pore opening (Fig. 1 I). Moreover, the in-
hibitory effect of Z-VAD.fmk can be overcome by increas-
ing the dose of the supernatant (Fig. 1 I). The AIF activity
that is retained in the MiniS column (but not that con-
tained in the flow-through) is completely resistant to inhi-
bition by Z-VAD.fmk (Fig. 4 B). However, when added
before Atr, Z-VAD.fmk becomes more efficient in inhibit-
ing AIF than when added after PT pore opening (Fig. 3 B).
Preincubation of mitochondria with Z-VAD.fmk, before
Atr is added, provokes the disappearance of the MiniS
column–retained protein peak corresponding to AIF (Fig.
3 A). This suggests that a Z-VAD.fmk–inhibitable enzyme
is required for the release and/or maturation of AIF.
In conclusion, the pharmacological data confirm that at
least three distinct activities are present in the supernatant
Figure 2. Overview of the FPLC separation procedure. Mitochondrial
intermembrane proteins were sequentially applied to MiniS cation ex-
change, MiniQ column anion exchange, or phenyl superose hydropho-
bicity columns as detailed in Materials and Methods and in Results. This
methodology allows for the separation of all biological activities analyzed
in this paper.
Figure 3. Selective retention of AIF ac-
tivity on a MiniS cation exchange column.
(A) Intermembrane proteins soluble in 50
mM Hepes-KOH (pH 6.75) were applied
to a MiniS FPLC column and eluted by 25
mM NaCl. Fractions (40 ml) were recov-
ered for further biological testing as in the
legend to Fig. 1. Data are shown for two
different experiments, one in which inter-
membrane proteins were obtained after ad-
dition of Atr (5 mM, 30 min; thin line) and
one in which intermembrane proteins were
obtained after preincubation of mitochon-
dria with 100 mM Z-VAD.fmk for 15 min
(thick line). (B) Profile of AIF activity ob-
tained in the presence or absence of 100
mM Z-VAD.fmk. Z-VAD.fmk was either
added to the mitochondria before treatment
with Atr (m) or it was added to the superna-
tant (Sn) of mitochondria after treatment
with Atr (h). (C) Z-VAD.afc–cleaving ac-
tivity measured in the presence or absence
of Z-VAD.fmk added to the supernatant.
(D) DNAse activity. Results are representa-
tive of ten independent experiments.386 Mitochondrial Release of Caspase-2 and -9
of mitochondria: (a) a caspase-like activity cleaving Z-VAD.
afc, (b) AIF, and (c) a DNAse.
Identification of Caspases-2 and -9 in the Mitochondrial Su-
pernatant. The Z-VAD.afc–cleaving activity is fully inhib-
ited by biotinylated VAD.fmk (ID50 , 1 mM), which co-
valently reacts with the large subunit of caspases (49, 50).
Therefore, we incubated the supernatant of Atr-treated mi-
tochondria or the partially purified Z-VAD.afc–cleaving
activity with biotinylated Z-VAD, and purified Z-VAD.bi-
otin–binding proteins by avidin affinity chromatography
(Fig. 2, and Fig. 5 A). Consistently, two of the major
Z-VAD.biotin–binding proteins contained in these prepa-
rations have z33 and 18 kD (Fig. 5 A). Other Z-VAD.
biotin–binding proteins found in the supernatant of Atr-
treated mitochondria (lane 2 of Fig. 5 A) are lost during the
purification process of the Z-VAD.afc–cleaving activity
(lane 7) or after affinity purification of Z-VAD.biotin–
binding proteins (lane 9), which might suggest that they
reflect nonspecific or low-affinity binding (Fig. 5 A). Two
closely related caspases, caspase-2 and -9, possess the larg-
est potentially Z-VAD.biotin–reactive subunit among all
known caspases, with z33 kD (51, 52). Accordingly, the
Z-VAD.biotin–binding activity found in liver mitochon-
dria reacted with antibodies specific for the NH2-terminal
subunit of caspase-2 (which recognizes the 48-kD pro-
caspase and the 33-kD intermediate form built up by the
NH2-terminal prodomain and the 18-kD large subunit of
the mature caspase-2) (Fig. 5 B). In addition, we found that
crude supernatants of Atr-treated mitochondria, purified
Z-VADase, and the Z-VAD.biotin–binding activity re-
acted with an antiserum specific for the large 18-kD sub-
unit of caspase-9 (which recognize the 48-kD procaspase,
the 33-kD intermediate, and the 18-kD large subunit of
the mature caspase-9) (Fig. 5 C). Crude mitochondrial su-
pernatants contain the caspase-2 and -9 zymogens (48 kD)
as well as their proteolytic activation products (Fig. 5, B
and C, lane 2), whereas the purified Z-VADase activity
(lanes 7 and 9 in Fig. 5, A–C) only contains the intermedi-
ate and mature forms of these caspases. When mitochon-
dria were treated with Z-VAD.fmk before induction of PT
(lane 3 in Fig. 5, A–C), only the procaspases were detected
in the mitochondrial supernatant. Submitochondrial frac-
tionation experiments indicate that the pro-forms of cas-
pase-2 and -9 are present in the mitochondrial intermem-
brane space (Fig. 6, A and B, lane 4) but absent from the
matrix or from purified inner and outer mitochondrial
membranes. Immunoelectron microscopy confirmed that
caspase-9 is located in the mitochondrial periphery rather
than in the outer mitochondrial membrane (Fig. 6 C).
Again, caspase-2 and -9 are found as zymogens (z48 kD)
in the intermembrane space when submitochondrial frac-
tionation is performed in the presence of Z-VAD.fmk (Fig.
Figure 4. Biochemical and functional
separation of biological activities. (A) The
flow-through of the MiniS column shown in
Fig. 3 (fractions 2–4) was recovered in 50
mM Tris-HCl (pH 8.5), applied to a MiniQ
anion exchange column, and eluted by in-
creasing the concentration of NaCl in frac-
tions of 150 ml. These fractions were sub-
jected to further evaluation as in the legend
to Fig. 1, namely quantitation of AIF activ-
ity (B), Z-VAD.afc–cleaving activity (C),
and DNAse activity (D). The numbers in
B–D refer to the fractions eluted from the
MiniQ column in A. Alternatively, super-
natants of Atr-treated mitochondria were
tested for AIF activity (E), Z-VAD.afc–
cleaving activity (F), or DNAse activity (G)
after addition of 1 mM ZnCl2 or 5 mM
EGTA. Results are representative of five in-
dependent determinations.387 Susin et al.
6, A and B, lane 8). In contrast, they become proteolyti-
cally activated when intermembrane proteins are purified
in the absence of Z-VAD.fmk (Fig. 6, A and B, lane 4),
suggesting that the intermembrane space contains all factors
required for caspase-2/9 (auto-)activation. The caspase-2–
and caspase-9–specific antibodies (which do not cross-react;
Fig. 5, F and G) both reduced the Z-VAD.afc–cleaving
activity contained in the supernatant of Atr-treated liver
mitochondria (Fig. 7 B). When combined, they reduce this
activity to background levels, indicating that both caspase-2
and -9 account for the Z-VAD.afc–cleaving activity (Fig.
7 B). In contrast, no Z-VAD.biotin–binding protein or
caspase-2/9 immunoreactivity was found in purified AIF
(Fig. 5, A–C, lane 6) or semipurified DNAse preparations
(not shown). Caspase-2 and -9 were detected in the super-
natant of Atr-treated mitochondria from different organs,
including kidney, brain, spleen, and heart (Fig. 5, D and E).
In conclusion, procaspase-2 and -9 are present in mito-
chondria of different organs and are released and activated
upon induction of PT.
Caspase-2 and -9 Are Apoptogenic and Redistribute during
Apoptosis Induction in a Bcl-2–inhibitable Fashion. As expected
from the fact that the Z-VADase does not cause isolated
nuclei to become hypoploid in vitro (Figs. 2–4), recombi-
nant caspase-2 and -9 have no direct apoptogenic effect in
a cell-free system involving purified nuclei cultured in the
absence of additional cytoplasmic factors (Fig. 7 A). How-
ever, caspase-2 and -9 do induce nuclear apoptosis, reduc-
tion of cell size, and phosphatidylserine exposure on the
outer leaflet of the plasma membrane when microinjected
into cells (Fig. 8), indicating that they can activate cellular
factors capable of inducing apoptosis. The purified Z-VAD.
fmk–resistant fraction of AIF also causes nuclear apoptosis
upon microinjection, and this effect is not inhibited by
Figure 5. Identification of the Z-VAD–
binding activity as caspase-2 and -9. (A) Pro-
teins reacting with biotinylated VAD.fmk in
the intermembrane space of liver mitochondria.
The supernatant of control mitochondria (lane
1) or of Atr-treated mitochondria (lanes 2 and
3), the flow-through of the MiniS column (see
Fig. 2 and Fig. 3 A; lanes 4 and 5), purified AIF
(lane 6), or the Z-VAD.afc–cleaving activity
eluting at 280 mM from the MiniQ column
(see Fig. 2 and Fig. 4 A; lanes 7 and 8) were allowed to react with biotinylated VAD.fmk, either without pretreatment (lanes 1, 2, 4, 6, and 7) or after
preincubation with Z-VAD.fmk (lanes 3, 5, and 8). Note that Z-VAD.fmk has been added to mitochondria before Atr (line 3). In addition, the proteins
reacting with biotinylated VAD.fmk retained on an avidin column were purified (lane 9). These proteins, which contained approximately similar levels
of Z-VAD.afc–cleaving activity (10 U) or z100 ng purified protein (lane 6) were separated by SDS-PAGE, blotted onto nitrocellulose, and subjected to
the detection of biotinylated VAD.fmk using an avidin-based detection system. (B and C) The same blot as in A was subjected to immunodetection with
antibodies specific for caspase-2 (B) or -9 (C). (D and E) Mitochondria from different organs were purified and cultured for 30 min in the presence or ab-
sence of 5 mM Atr, followed by immunoblot detection of caspase-2 (D) or -9 (E). Results are representative of two to four independent experiments. (F
and G) Specificity control of caspase-2– and caspase-9–specific antisera. Recombinant caspase-2 (lane 1), -3 (lane 2), or -9 (lane 3) was immunoblotted
(100 ng/lane), followed by immunodetection with the caspase-2 (F) or caspase-9 (G)–specific antibody. Similarly, caspase-2– and caspase-9–specific anti-
bodies fail to recognize caspase-6 and -7 (not shown).
Figure 6. Submitochondrial localization of caspase-2 and -9. Purified mitochondria were either lysed by osmotic shock (total preparation, lane 1) or
were subjected to fractionation into matrix (lanes 2 and 6), inner membrane (lanes 3 and 7), intermembrane (lanes 4 and 8), or outer membrane (lanes 5
and 9) proteins, in the absence (lanes 2–5) or presence (lanes 6–9) of 100 mM Z-VAD.fmk throughout each single step of the fractionation procedure.
Thereafter, equivalent amounts of protein (15 mg/lane) were subjected to immunoblot detection of caspase-2 (A) and -9 (B). A representative immuno-
electron micrograph of mitochondria labeled with a specific caspase-9 antibody is also shown (C).388 Mitochondrial Release of Caspase-2 and -9
Z-VAD.fmk (not shown). These data indicate that several
mitochondrial factors (AIF, caspase-2, and caspase-9) may
have a primary apoptogenic effect in vivo.
To further investigate the in vivo impact of caspase-2
and -9, we analyzed their subcellular distribution during
the process of apoptosis. Immunofluorescence detection re-
vealed a granular pattern of distribution of both caspases,
similar to that of cytochrome c in Rat-1 fibroblasts (Fig. 9),
U937 myelomonocytic cells, SHEP neuroblastoma cells,
and 2B4.11 T cell hybridoma cells (not shown). Upon in-
duction of apoptosis with staurosporine A (Fig. 9), etopo-
side, or ceramide (not shown), the granular pattern of fluo-
rescence is replaced by a diffuse pattern, indicating the
abolition of subcellular compartmentalization of these mol-
ecules. This interpretation was confirmed by subcellular
fractionation. Mitochondria and cytosols from T cell hybri-
doma cells induced to undergo apoptosis in response to the
synthetic glucocorticoid receptor agonist DEX were puri-
fied. As shown in Fig. 10, in this cell line both procaspase-2
and -9 are localized in mitochondria. Some caspase-9 but
no caspase-2 were found in the cytosolic fraction of un-
treated cells. Upon stimulation with DEX, procaspase-2
Figure 7. Neutralization of
the Z-VAD.afc–cleaving activ-
ity by immunodepletion of
caspase-2 and -9. Soluble inter-
membrane proteins were de-
pleted of caspase-2 and/or -9 us-
ing specific antisera, and the AIF
activity (A) or Z-VAD.afc-cleav-
ing activity (B) was assessed.
Typical results out of three ex-
periments are shown.
Figure 8. Apoptosis induction
by microinjection of recombinant
caspases. Rat-1 fibroblasts were
left untreated or cultured with
etoposide (1 mM, 6 h), in the ab-
sence or presence of Z-VAD.fmk
(100 mM), to obtain a positive or
negative control of apoptotic
morphology, respectively. Alter-
natively, cells pretreated with
Z-VAD.fmk (100 mM, 60 min)
or left untreated were micro-
injected with buffer only or
with  recombinant caspase-2 or -9
(3 U/ml). Microinjected viable
cells (100–200 per session, two to
five independent sessions of injec-
tion) could be identified because
the injectate contained FITC-
dextran (0.25% [wt/vol], green
fluorescence; not shown). Micro-
photographs representing the
dominant (.70%) phenotype of
microinjected cells stained either
with Hoechst 33342 (blue fluo-
rescence, A) or with Annexin V
(red fluorescence, B) are shown
after 90 min of culture. Z-VAD.
fmk pretreatment prevented phos-
phatidylserine exposure induced by
etoposide, caspase-2, or caspase-9,
as measured with Annexin V (not
shown).389 Susin et al.
and -9 redistribute to the cytosol where they are at least
partially processed, as revealed by the presence of bands
corresponding to 33 kD (caspase-2) and 33 and 18 kD
(caspase-9). Both the redistribution of these caspases and
their activation are inhibited in cells overexpressing Bcl-2
(Fig. 10), thus confirming the inhibitory effect of Bcl-2 on
caspase release observed in isolated mitochondria (Fig. 1).
In summary, upon induction of apoptosis, the pro-forms
of caspase-2 and -9 redistribute from mitochondria to the
cytosol in a Bcl-2–inhibitable fashion. These caspases be-
come activated after or during the mitochondrial release
and may actively participate in the apoptotic process.
Discussion
Involvement of Several Mitochondrial Proteins in the Apoptotic
Degradation Phase. Although some investigators have tac-
itly implied that cytochrome c would be the only relevant
apoptogenic activity released from mitochondria (13–15,
32, 33, 53), the data presented in this paper suggest that mi-
tochondria release several apoptogenic factors. These fac-
tors include AIF (7), a DNAse, and at least two caspase
zymogens, namely caspase-2 and -9. Caspase-2 and -9
are found in the intermembrane space of mitochondria
from five different organs (liver, kidney, heart, brain, and
spleen), as well as in several cell lines (including different
lymphoid and neuroblastoma cell lines), and are released in
a Bcl-2–inhibitable fashion upon induction of PT in iso-
lated mitochondria and upon apoptosis induction in cells. It
has been reported very recently that a variable portion (10–
90%) of caspase-3 zymogen is located in the intermem-
brane space of mitochondria from different cell types (54).
However, in mouse liver, we have failed to detect caspase-3,
in accord with the very minor portion of caspase-3 zy-
mogen detected in human liver mitochondria (54). More-
over, we failed to detect caspase-6, -7, or -8 in mouse liver
mitochondria (not shown). As demonstrated here, during
or after the release from mitochondria, the caspase-2 and -9
zymogens become proteolytically processed and enzymati-
cally active. At present, the mechanisms responsible for this
phenomenon are not clear. As a possibility, the release of
caspase zymogens from mitochondria alters the equilibrium
between caspase activators and local caspase inhibitors,
thereby favoring their activation. Alternatively, procaspases
could become activated by extramitochondrial factors (in
cells) and/or by mitochondrial surface proteins with whom
they normally cannot interact (in isolated mitochondria).
Irrespective of the exact mode of activation, cytochrome c
is not a rate-limiting factor for caspase-2 and -9 activation
upon mitochondrial release, as suggested by experiments in
which cytochrome c has been immunodepleted from mito-
chondrial supernatants. However, these results do not rule
Figure 9. Loss of subcellular compartmentalization of cytochrome c,
caspase-2, and caspase-9. Rat-1 cells were left untreated or were cultured
in the presence of staurosporine (4 h, 1 mM), fixed, and stained to deter-
mine the subcellular distribution of the indicated molecules by indirect
immunofluorescence analysis.
Figure 10. Redistribution of caspase-2 and -9 from the mitochon-
drion. T cell hybridoma cells transfected with a Neo control vector or
with Bcl-2 were cultured in the absence or presence of 1 mM DEX, fol-
lowed by subcellular fractionation, as described in Materials and Methods.
Equivalent amounts of proteins were subjected to immunoblot analysis in
order to determine the subcellular localization and activation of cyto-
chrome c (A), caspase-2 (B), or caspase-9 (C). Results are representative
of three independent determinations.390 Mitochondrial Release of Caspase-2 and -9
out the possibility that a rather low level of cytochrome c
and/or early interactions between caspase zymogens and
cytochrome c, within the intermembrane space, may par-
ticipate in caspase activation. In addition to caspases, mito-
chondria also release AIF. Whereas one portion of AIF ac-
tivity is well inhibited by caspase inhibitors (Z-VAD.fmk),
another, biochemically distinct portion of AIF activity is
Z-VAD.fmk resistant. Since this latter AIF activity disap-
pears when mitochondria are pretreated with Z-VAD.fmk,
it appears plausible that caspase activation is required for its
generation and/or action. Using a different protocol of AIF
purification (7, 8), in which both AIF species copurify, we
have previously overlooked this phenomenon. In any case,
the inhibitory profile of AIF, whose molecular character-
ization is still in progress, clarifies that it is not identical to
caspase-2, -9, or -3 (which are all inhibited by Z-VAD.
fmk) nor with DFF/CAD (which is inhibited by ATA and
acts on naked DNA) (35, 47). Altogether, these data indi-
cate that mitochondria contain several potentially apopto-
genic proteins in addition to cytochrome c.
Cross-talk between Caspases and Mitochondria at Multiple
Levels. The data reported here add to the intricate rela-
tion between mitochondria and the caspase activation cas-
cade. First, in apoptosis-induction pathways directly cou-
pled to caspase activation, namely those involving ligation
of death domain–containing surface receptors (prototype:
CD95), caspases are activated at a premitochondrial stage,
before the mitochondrial membrane permeability is per-
turbed (8, 55, 56). Thus, certain caspases (e.g., caspase-8 in
the CD95 pathway) can be activated upstream of mito-
chondria and can, as shown by addition of recombinant
caspase to isolated mitochondria, directly disrupt the barrier
function of mitochondrial membranes (10, 57). Second,
mitochondria contain caspase zymogens, in particular pro-
caspase-2, -3, and -9 (54; and this paper), which are re-
leased upon permeabilization of the outer mitochondrial
membrane. Third, mitochondrial intermembrane proteins,
including cytochrome c and caspase-2 and -9, can activate
postmitochondrial caspases, including caspase-3, -6, and -7
(8, 55), which in turn can directly act on mitochondrial
membranes (8, 10, 57) and/or redistribute into mitochon-
dria, as has been recently shown for caspase-7 (58). Thus,
they would engage in a self-amplifying feedback loop in
which mitochondrial membrane permeabilization causes
caspase activation and vice versa.
This scenario helps to clarify the complex relationship
between caspase activation and the (presumably) mito-
chondrial Bcl-2/Bcl-XL checkpoint of the apoptotic pro-
cess. Activation of upstream caspases (e.g., caspase-8) is not
controlled by Bcl-2/Bcl-XL (55, 56, 59). If caspase-8 (or
secondarily, caspase-8–activated caspases) succeed in pro-
teolytically inactivating Bcl-2/Bcl-XL and/or bypassing its
mitochondrial membrane-stabilizing effect, they can in-
duce apoptosis (8, 10, 55, 60, 61). If not, Bcl-2 interrupts
the apoptotic cascade by retaining caspase-activating agents
such as cytochrome c (7, 15), AIF (7), and procaspase-2 and
-9 (this paper) in the mitochondrial intermembrane space.
This would explain how Bcl-2 abolishes the activation of
downstream caspases, including caspase-3 and -6 (8, 55, 62,
63). In the nematode Caenorhabditis elegans, the death-regu-
latory machine is composed of three core interacting pro-
teins: CED-4 (the equivalent to mammalian Apaf-1), the
caspase CED-3, and the Bcl-2 homologue CED-9. Simi-
larly, in mammalian cells Bcl-XL, Apaf-1, and caspase-9
have been shown to interact (64). It is tempting to specu-
late that these complexes are formed at the mitochondrial
outer membrane/intermembrane interface, where at least
two of the three molecules reside. However, at present it is
not clear whether the Bcl-XL/Apaf-1/caspase-9 complex
participates in the Bcl-2/Bcl-XL–mediated regulation of
mitochondrial membrane permeability or whether it is
only formed after permeabilization of the outer mitochon-
drial membrane. If Apaf-1 is truly a cytosolic protein, as
suggested previously (32, 33), then this latter possibility
would apply.
Integrator/Coordinator Function of Mitochondria in Apoptosis.
Apoptosis-induction pathways directly coupled to caspase
activation such as CD95 are rare. In most cases, apoptosis
induction involves other second messengers such as cer-
amide, Ca21, alterations in redox status, or changes in the
expression level, subcellular distribution, and/or posttrans-
lational modifications of Bcl-2 homologues. In all of these
cases, mitochondria can respond by increasing the perme-
ability of their membranes (4–17, 21, 22, 25–31), suggest-
ing that they can integrate many different “private” proap-
optotic pathways and unify them in one common pathway.
Thus, the mitochondrion functions as an integrator of dif-
ferent death pathways.
In addition, mitochondria coordinate the cellular events
of the apoptotic degradation at several levels. At the first
level, mitochondria release factors capable of activating hy-
drolases (caspases and nucleases). As shown here, mito-
chondria release at least two caspases (caspase-2 and -9),
which have been considered to be apical in a number of
different apoptosis-induction pathways (34, 65–68). By vir-
tue of these caspases, and caspase-activating factors such as
cytochrome c, AIF, and a DNAse, mitochondria thus can
trigger a series of catabolic reactions that participate in the
acquisition of apoptotic morphology. At a second level,
mitochondria generate reactive oxygen species due to in-
terruption of electron transport on the respiratory chain,
which lack cytochrome c, the electron shuttle between
complexes III and IV (69). At a third level, PT pore open-
ing causes a loss of mitochondrial antioxidant function and
a cessation of ATP synthesis. These latter changes probably
suffice to kill cells. Thus, overexpression of Bax (31, 36),
Bak (70), or c-Myc (70), glucocorticoid receptor ligation
(9, 71), DNA damage (9), or HIV-1 infection (72), all
stimuli that usually induce apoptosis, can induce a nonap-
optotic cell death in the presence of caspase inhibitors.
Cells exposed to such proapoptotic stimuli in the context
of caspase inhibitors undergo delayed cytolysis and fail to
manifest several hallmarks of apoptotic death, including
DNA fragmentation (9, 31, 36, 70–72). However, they do
manifest an increased permeability of mitochondrial mem-
branes with dissipation of the inner mitochondrial trans-391 Susin et al.
membrane potential (DCm) and/or the release of cyto-
chrome c through the outer mitochondrial membrane (9,
16, 17, 31, 36, 71). Nonetheless, in normal conditions,
in the absence of caspase inhibitors, the mitochondrial
changes are closely tied to caspase activation, as can be de-
duced from the strong mutual relationship between mito-
chondrial membrane permeabilization and caspase activa-
tion (see above).
In summary, the mitochondrial release of several inde-
pendent apoptogenic molecules, including caspase-2 and
-9, reinforces the tight link existing between the disruption
of mitochondrial membrane barrier function and the acti-
vation of the apoptotic degradation phase. Mitochondria
fulfill a double role in apoptosis. In addition to integrating
different proapoptotic initiation cascades, they coordinate
the death response.
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